SecBot SecBot
PRESS-RELEASE ·Filed Aug 10, 2026

ORKA

Oruka Therapeutics, Inc.
BULLISH
Impact 7/10
Horizonmonths Processed3mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▲ Bullish

The EPS miss is noise for a pre-commercial biotech; the stock's path hinges on EVERLAST-A Week 28 data (Q3 2026) and EVERLAST-B Week 16 data (Q4 2026). Traders should watch for any early efficacy signals or safety flags from the 28-week readout, which will inform the Phase 3 design and BLA filing timeline. The $1.1B cash runway removes near-term financing risk.

DirectionBullish
Confidencehigh
Horizonmonths

Drugs in focus

ORKA drug pipeline →

ORKA-001

▲ Bullish Named in this press release
Impact
Phase
Phase 2b
Time to market
If Phase 3 trials begin in 1H 2027 and run successfully, a BLA submission and potential FDA approval would likely be several years away, possibly in the 2029-2030 timeframe. The company has stated its $1.1 billion cash position funds operations through a BLA filing.
Next catalyst
None dated

What to watchThe key catalyst to watch is the EVERLAST-A 52-week data expected in December 2026, which will demonstrate whether ORKA-001's skin-clearing responses hold up a full year after just two doses. Strong durability would reinforce the ultra-durable dosing thesis and support the Phase 3 design. Weak durability would challenge the core value proposition. Phase 3 initiation in 1H 2027 and ORKA-002 Phase 2 data in Q1 2027 are secondary catalysts. The $1.1B cash runway removes financing overhang through a BLA filing.

Price Chart

Loading chart...

Executive Summary

Oruka Therapeutics reported Q2 2026 results in line with pre-revenue expectations: EPS of -$0.55 (consensus -$0.50) was a 10% miss due to higher R&D spend ($43.3M vs $24.1M YoY), but the stock is driven by pipeline catalysts rather than quarterly profit. The company has $1.1B cash runway through a planned BLA filing for ORKA-001, with multiple upcoming readouts including EVERLAST-A Week 28 data in Q3 2026, EVERLAST-B Week 16 data in Q4 2026, and Phase 3 initiation in 1H 2027.

Key Financial Metrics

EPS
−$0.55
est −$0.50 · -10.0%
Revenue
$0.00
est $0.00
Rating
miss

Key Facts

  • Q2 2026 net loss $41.2M ($0.55/share) vs consensus -$0.50, a 10% EPS miss due to higher R&D expenses
  • Cash, cash equivalents and marketable securities of $1.1B as of June 30, 2026
  • EVERLAST-A Week 28 data expected end of Q3 2026; 52-week data for all participants expected December 2026
  • EVERLAST-B fully enrolled (187 subjects), Week 16 data expected Q4 2026
  • Phase 3 program for ORKA-001 expected to begin 1H 2027
  • ORCA-SURGE Week 16 data accelerated to Q1 2027; ORCA-SPLASH Phase 2 in HS initiated
  • ORKA-004 (anti-TL1A) to enter clinic in Q4 2026 with planned Phase 2 combo studies in 2027
  • Amended IL-23 license with Paragon to include inflammatory bowel disease (IBD)
  • R&D expenses $43.3M (up 80% YoY), G&A $6.9M (up 58% YoY), reflecting pipeline expansion

Financial Impact

EPS surprise of -$0.55 vs -$0.50 consensus (-10%), R&D burn accelerating to $43.3M/quarter, cash runway $1.1B sufficient through BLA filing

epscashr&d expensesnet loss

Risk Factors

  • EVERLAST-A Week 28 data could show waning efficacy vs Week 16 (loss of PASI 100 responses)
  • EVERLAST-B dose-ranging data may not clearly differentiate from existing IL-23 inhibitors
  • Clinical hold or safety signal in any of the three ongoing Phase 2 trials
  • Competitive pressure from bimekizumab, guselkumab, and emerging oral therapies

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
95% bullish (20 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3341704

Track record

40 reports on ORKA

Performance horizon

7 of 10 bullish or bearish reports moved the stock their way by T+20. Best: +80.05% at T+60 after the Jun 1, 2026 report. 11 of 11 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 3/10 Entry $102.46 Now $99.24 −3.14% settles Dec 15
  2. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry price pending
  3. Nov 13, 20263d ago Insider Cluster Neutral 2/10 Entry $106.15 Now $99.24 −6.51% settles Dec 15
  4. Nov 13, 20263d ago Insider Cluster Neutral 2/10 Entry $104.89 Now $99.24 −5.39% settles Dec 15
  5. Nov 12, 20264d ago 144 Neutral 2/10 Entry $105.35 Now $99.24 −5.80% settles Dec 14
  6. Nov 12, 20264d ago 144 Neutral 2/10 Entry $105.35 Now $99.24 −5.80% settles Dec 14
  7. Nov 9, 20267d ago Press Release Neutral 5/10 Entry $109.50 Now $99.24 −9.37% settles Dec 9
  8. Nov 2, 202614d ago Institutional Cluster Neutral 2/10 Entry $99.55 Now $99.24 −0.31% settles Dec 2
  9. Nov 2, 202614d ago 144 Neutral 3/10 Entry $99.55 Now $99.24 −0.31% settles Dec 2
  10. Oct 26, 202621d ago 8-K Bullish 6/10 Entry $90.33 Now $99.24 +9.86% settles Nov 23
Showing 10 of 40

US Market Status

Market Closed · Opens Wed (10h 9m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 10, 2026